Glooko has secured US Food and Drug Administration (FDA) clearance for EndoTool IV Cloud, priming the cloud-based insulin dosing platform for commercialisation across hospital settings.
Endotool is a computer software system that supports individualised insulin dosing for critically ill hospitalised patients who require intravenous insulin therapy. Glooko inherited EndoTool, the first iteration of which secured FDA clearance in 2006, following its acquisition of Monarch Medical Technologies in September 2025. The terms of the acquisition were not publicly disclosed.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The cloud-based model is designed to reduce the need of on premise infrastructure and supports a more scalable approach for hospitals adopting or expanding the use of EndoTool IV, Glooko stated.
Using the same core insulin dosing algorithm as EndoTool IV, Glooko anticipates that the introduction of cloud-based functionality will help deploy the tool across hospital settings and improve the system’s flexibility.
Glooko expects EndoTool IV Cloud to launch commercially in the US by the end of 2026.
Paul Chidester, medical director, EndoTool at Glooko, commented: “With EndoTool IV Cloud, we are preserving the same trusted clinical foundation and insulin dosing algorithm while making the solution easier to deploy, maintain and scale for hospital teams.”
The global diabetes population is projected to hit 643 million by 2030, as per data from the International Diabetes Federation.
Glooko’s acquisition of Monarch reflected a continuation of the company’s efforts to develop its diabetes platform and expand its global footprint. In November 2024, Glooko completed a $100m Series F financing round to expand into the Middle East and Asia.
To further its global presence, Glooko partnered with Danish digital therapeutics company Hedia in 2025 to launch a combined diabetes care technology provision in the UK to enhance support for diabetic patients who require bolus insulin dosing support in their daily management.
Also in 2025, Glooko continued adding to its existing roster of over 200 integrated devices, including an integration with Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) device, thereby broadening the reach of Glooko’s platform to around 4.5 million patients who use Abbott’s system.
